AstraZeneca gets European regulatory nod for oral diabetes treatment

Writer, Stock Market Wire
Friday, February 1, 2019 - 13:59

AstraZeneca said European regulators had offered a positive opinion for the oral use of its treatment for type-one diabetes.

The Committee for Medicinal Products for Human Use of the European Medicines Agency had also recommended a new indication for the marketing authorisation of the treatment, Forxiga. Forxiga was the first oral medicine to receive a positive recommendation from the EMA for use in type-one diabetes as an adjunct to insulin, when insulin alone did not provide adequate glycaemic control.

'People with type-one diabetes have not seen oral treatment innovation in decades and we believe today's announcement signals an important advancement for them, as well as a broader understanding of the well-established clinical profile of Forxiga for people living with metabolic diseases,' head of cardiovascular, renal and metabolism Elisabeth Bjork said.

At 1:59pm: (LON:AZN) AstraZeneca PLC share price was +33.5p at 5565.5p

Related content

AstraZeneca drug approved in US to reduce risk of heart failure in type-2 diabetes patients

AstraZeneca said its type-2 diabetes drug was approved by US regulators to reduce the risk of hospitalisation for heart failure in adults with type-2 diabetes...

Mon, 21/10/2019 - 07:31

AstraZeneca's breast cancer drug granted priority review in US

AstraZeneca said the US Food and Drug Administration had granted the priority review for its metastatic breast cancer drug.

The review date for the...

Thu, 17/10/2019 - 08:20

Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC

Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 6700p (from 6550p).

Broker Forecasts data provided...

Tue, 15/10/2019 - 09:20

Dudley helps BP overcome deadly legacy

While he will probably be disappointed with BP’s share price performance during his nine-year tenure as the oil major’s CEO, Bob Dudley will be...

Fri, 04/10/2019 - 15:15

AstraZeneca's respiratory drug gets regulatory nod in US for self-administration

AstraZeneca said the US Food and Drug Administration had approved the self-administration of the company’s respiratory medication in a pre-filled pen.

The company said...

Fri, 04/10/2019 - 07:26